RecruitingPhase 1NCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
A Randomized, Open-label, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Tulisokibart Delivered by 2 Different Autoinjectors in Healthy Participants
Sponsor
Merck Sharp & Dohme LLC
Enrollment
330 participants
Start Date
Mar 5, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria1
- Has a body-mass index (BMI) between 18 and 32 kg/m\^2
Exclusion Criteria2
- Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection
- Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALTulisokibart Form 1
Solution for injection.
BIOLOGICALTulisokibart Form 2
Solution for injection.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07405177
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
NCT074073481 location
A Study of LY3971297 in Healthy Participants
NCT061482727 locations
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
NCT070970124 locations
Evaluation of [11C]ZTP-1 to Image PDE4B
NCT076253451 location